This clinical trial sought to investigate if adding immunotherapy to standard chemo before surgery improves outcomes for patients with high-risk, early-stage triple-negative breast cancer. According to the Irish Cancer Society, about 1 in every 83 breast cancers is triple negative. It also tends to be more common in younger women.